시장보고서
상품코드
1151921

세계의 브루가다 증후군 시장 규모 조사와 예측 : 진단, 치료, 최종사용자별, 지역별 분석(2022-2029년)

Global Brugada Syndrome Market Size study & Forecast, by Diagnosis, Treatment, and End User and Regional Analysis, 2022-2029

발행일: | 리서치사: Bizwit Research & Consulting LLP | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 브루가다 증후군 시장은 2021년에 약 13억 2000만 달러로 평가되며, 예측 기간인 2022-2029년에는 6.5%를 넘는 성장률로 성장할 것으로 예측되고 있습니다.

목차

제1장 주요 요약

  • 시장 스냅숏
  • 세계·부문별 시장 추정·예측, 2019-2029년
    • 브루가다 증후군 시장 : 지역별, 2019-2029년
    • 브루가다 증후군 시장 : 진단별, 2019-2029년
    • 브루가다 증후군 시장 : 치료별, 2019-2029년
    • 브루가다 증후군 시장 : 최종사용자별, 2019-2029년
  • 주요 동향
  • 조사 방법
  • 조사 전제조건

제2장 세계의 브루가다 증후군 시장 : 정의와 범위

  • 조사의 목적
  • 시장의 정의와 범위
    • 조사 대상 범위
    • 산업의 진화
  • 조사 대상년
  • 통화 환산율

제3장 세계의 브루가다 증후군 시장 역학

  • 브루가다 증후군 시장의 영향 분석(2019-2029년)
    • 시장 촉진요인
      • 심장 관련 질환의 발생률 증가
      • 브루가다 증후군의 유병률 상승
      • 주요 시장 기업의 전략적 구상
    • 시장이 해결해야 할 과제
      • 브루가다 증후군에 관련된 높은 치료비
      • 불리한 상환 시나리오
    • 시장 기회
      • 유전성 증후군의 인지도 향상
      • 제약·바이오테크놀러지 산업의 성장

제4장 세계의 브루가다 증후군 시장 : 산업 분석

  • Porter's 5 Force 모델
    • 공급 기업의 교섭력
    • 구매자의 교섭력
    • 신규 진출업체의 위협
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계
  • Porter's 5 Force 모델에 대한 미래적 어프로치(2019-2029년)
  • PEST 분석
    • 정치적
    • 경제적
    • 사회적
    • 기술적
  • 투자 채택 모델
  • 애널리스트의 결론·제안
  • TOP 투자 기회
  • 주요 성공 전략

제5장 리스크 평가 : COVID-19의 영향

  • COVID-19가 업계에 미치는 전체적인 영향 평가
  • COVID-19 이전과 COVID-19 이후 시장 시나리오

제6장 세계의 브루가다 증후군 시장 : 진단별

  • 시장 스냅숏
  • 세계의 브루가다 증후군 시장 : 진단별, 실적 - 잠재력 분석
  • 세계의 브루가다 증후군 시장 : 진단별 추정·예측 2019-2029년
  • 세계의 브루가다 증후군 시장 : 하위 부문 분석
    • 심전도 검사
    • 전기생리학(EP) 검사
    • 유전자 검사
    • 기타

제7장 세계의 브루가다 증후군 시장 : 치료별

  • 시장 스냅숏
  • 세계의 브루가다 증후군 시장 : 치료법별, 실적 - 잠재력 분석
  • 세계의 브루가다 증후군 시장 : 치료법별 추정·예측 2019-2029년
  • 세계의 브루가다 증후군 시장 : 하위 부문 분석
    • 삽입형 제세동기
    • 약물 요법

제8장 세계의 브루가다 증후군 시장 : 최종사용자별

  • 시장 스냅숏
  • 세계의 브루가다 증후군 시장 : 최종사용자별 실적 - 잠재력 분석
  • 세계의 브루가다 증후군 시장 : 최종사용자별 추정·예측 2019-2029년
  • 세계의 브루가다 증후군 시장 : 하위 부문 분석
    • 병원·진료소
    • 외과 센터
    • 진단 센터
    • 기타

제9장 세계의 브루가다 증후군 시장 : 지역별 분석

  • 브루가다 증후군 시장, 지역별 시장 스냅숏
  • 북미
    • 미국
      • 진단별 추정·예측, 2019-2029년
      • 치료별 추정·예측, 2019-2029년
      • 최종사용자별 추정·예측, 2019-2029년
    • 캐나다
  • 유럽의 브루가다 증후군 시장 스냅숏
    • 영국
    • 독일
    • 프랑스
    • 스페인
    • 이탈리아
    • 기타 유럽 지역
  • 아시아태평양의 브루가다 증후군 시장 스냅숏
    • 중국
    • 인도
    • 일본
    • 호주
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카의 브루가다 증후군 시장 스냅숏
    • 브라질
    • 멕시코
  • 세계의 기타 지역

제10장 경쟁 정보

  • 주요 시장 전략
  • 기업 개요
    • Novartis AG
      • 주요 정보
      • 개요
      • 재무(데이터 입수가 가능한 경우)
      • 제품 개요
      • 최근 개발 상황
    • F. Hoffmann-La Roche Ltd
    • Boehringer Ingelheim International GmbH.
    • Pfizer Inc.
    • Ionis Pharmaceuticals Inc.
    • Abbott
    • Novo Nordisk A/S
    • Takeda Pharmaceutical Company Limited.
    • AstraZeneca
    • Cytokinetics, Inc.

제11장 조사 프로세스

  • 조사 프로세스
    • 데이터 마이닝
    • 분석
    • 시장 추정
    • 밸리데이션
    • 출판
  • 조사 속성
  • 조사 전제조건
KSA 22.11.24

Global Brugada Syndrome Market is valued at approximately USD 1.32 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2022-2029. Brugada Syndrome is a rare genetic disorder that affects the way electrical signals pass through the heart. It is an autosomal dominant genetic disorder and can be inherited from just one parent. Brugada Syndrome causes disruptions to the normal rhythm of the heart. Signs and symptoms associated with Brugada Syndrome include dizziness. fainting. gasping and laboured breathing, irregular heartbeats, or palpitations as well as extremely fast and chaotic heartbeat among others. The increasing incidence of heart-related diseases and growing prevalence of Brugada Syndrome as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to the World Health Organization (WHO)'s estimates - as of 2019, globally around 17.9 million people lost their lives due to CVDs, witnessing for over 32% of all global deaths. In addition, around 85% CVD related deaths are caused by heart attack stroke. Moreover, as per The National Organization for Rare Disorders - in 2019, the prevalence of Brugada Syndrome in the United States was estimated at 5 in 10,000 people. Also, rising awareness of genetic syndromes and growing pharmaceuticals & biotechnology industry would create lucrative growth prospects for the market over the forecast period. However, the high treatment cost associated with Brugada Syndrome stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Brugada Syndrome Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as the presence of key market players as well as availability of well-established healthcare infrastructure in the region. Whereas the Asia Pacific is expected to grow with the highest CAGRduring the forecast period, owing to factors such as the rising prevalence of Brugada Syndrome as well as growing healthcare infrastructure in the region.

Major market players included in this report are:

Novartis AG

F. Hoffmann-La Roche Ltd

Boehringer Ingelheim International GmbH.

Pfizer Inc.

Ionis Pharmaceuticals Inc.

Abbott

Novo Nordisk A/S

Takeda Pharmaceutical Company Limited.

AstraZeneca

Cytokinetics, Inc.

Recent Developments in the Market:

  • In October 2020, USA-based Abbott Laboratories launched new Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronisation Therapy Defibrillator (CRT-D) devices. These new devices are intended for the patient suffering from abnormal heart rhythms and heart failure.
  • In December 2021, Massachusetts, USA-based Boston Scientific announced a clinical trial of its first modular cardiac rhythm implant system. This new system is comprised of a leadless pacemaker and an implantable cardioverter defibrillator. This new system aimed at controlling the abnormal beating of the heart.

Global Brugada Syndrome Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered Diagnosis, Treatment, End User, Region

Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Diagnosis

Electrocardiogram

Electrophysiology Test

Genetic Testing

Others

By Treatment

Implantable Cardioverter-Defibrillator

Drug Therapy

By End User

Hospitals & Clinics

Surgical Centers

Diagnostic Centers

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Brugada Syndrome Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Brugada Syndrome Market, by Diagnosis, 2019-2029 (USD Billion)
    • 1.2.3. Brugada Syndrome Market, by Treatment, 2019-2029 (USD Billion)
    • 1.2.4. Brugada Syndrome Market, by End User, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Brugada Syndrome Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Brugada Syndrome Market Dynamics

  • 3.1. Brugada Syndrome Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of heart-related diseases.
      • 3.1.1.2. Growing prevalence of Brugada Syndrome.
      • 3.1.1.3. Strategic initiatives from leading market players.
    • 3.1.2. Market Challenges
      • 3.1.2.1. High treatment cost associated with Brugada Syndrome.
      • 3.1.2.2. Unfavourable reimbursement scenarios.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising awareness of genetic syndromes.
      • 3.1.3.2. Growing pharmaceuticals & biotechnology industry.

Chapter 4. Global Brugada Syndrome Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Brugada Syndrome Market, by Diagnosis

  • 6.1. Market Snapshot
  • 6.2. Global Brugada Syndrome Market by Diagnosis, Performance - Potential Analysis
  • 6.3. Global Brugada Syndrome Market Estimates & Forecasts by Diagnosis 2019-2029 (USD Billion)
  • 6.4. Brugada Syndrome Market, Sub Segment Analysis
    • 6.4.1. Electrocardiogram
    • 6.4.2. Electrophysiology (EP) Test
    • 6.4.3. Genetic Testing
    • 6.4.4. Others

Chapter 7. Global Brugada Syndrome Market, by Treatment

  • 7.1. Market Snapshot
  • 7.2. Global Brugada Syndrome Market by Treatment, Performance - Potential Analysis
  • 7.3. Global Brugada Syndrome Market Estimates & Forecasts by Treatment 2019-2029 (USD Billion)
  • 7.4. Brugada Syndrome Market, Sub Segment Analysis
    • 7.4.1. Implantable Cardioverter-Defibrillator
    • 7.4.2. Drug Therapy

Chapter 8. Global Brugada Syndrome Market, by End User

  • 8.1. Market Snapshot
  • 8.2. Global Brugada Syndrome Market by End User, Performance - Potential Analysis
  • 8.3. Global Brugada Syndrome Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
  • 8.4. Brugada Syndrome Market, Sub Segment Analysis
    • 8.4.1. Hospitals and Clinics
    • 8.4.2. Surgical Centers
    • 8.4.3. Diagnostic Centers
    • 8.4.4. Others

Chapter 9. Global Brugada Syndrome Market, Regional Analysis

  • 9.1. Brugada Syndrome Market, Regional Market Snapshot
  • 9.2. North America Brugada Syndrome Market
    • 9.2.1. U.S. Brugada Syndrome Market
      • 9.2.1.1. Diagnosis breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Treatment breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. End User breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Brugada Syndrome Market
  • 9.3. Europe Brugada Syndrome Market Snapshot
    • 9.3.1. U.K. Brugada Syndrome Market
    • 9.3.2. Germany Brugada Syndrome Market
    • 9.3.3. France Brugada Syndrome Market
    • 9.3.4. Spain Brugada Syndrome Market
    • 9.3.5. Italy Brugada Syndrome Market
    • 9.3.6. Rest of Europe Brugada Syndrome Market
  • 9.4. Asia-Pacific Brugada Syndrome Market Snapshot
    • 9.4.1. China Brugada Syndrome Market
    • 9.4.2. India Brugada Syndrome Market
    • 9.4.3. Japan Brugada Syndrome Market
    • 9.4.4. Australia Brugada Syndrome Market
    • 9.4.5. South Korea Brugada Syndrome Market
    • 9.4.6. Rest of Asia Pacific Brugada Syndrome Market
  • 9.5. Latin America Brugada Syndrome Market Snapshot
    • 9.5.1. Brazil Brugada Syndrome Market
    • 9.5.2. Mexico Brugada Syndrome Market
  • 9.6. Rest of The World Brugada Syndrome Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Novartis AG
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. F. Hoffmann-La Roche Ltd
    • 10.2.3. Boehringer Ingelheim International GmbH.
    • 10.2.4. Pfizer Inc.
    • 10.2.5. Ionis Pharmaceuticals Inc.
    • 10.2.6. Abbott
    • 10.2.7. Novo Nordisk A/S
    • 10.2.8. Takeda Pharmaceutical Company Limited.
    • 10.2.9. AstraZeneca
    • 10.2.10. Cytokinetics, Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제